Ambee Pharmaceuticals Plc

AMBEEPHA

BD0451AMBPH6

Pharmaceuticals

End-of-day quote Dhaka S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
719.9 ^BDT	+7.50%		+0.19%	-11.73%

Feb. 06	Ambee Pharmaceuticals PLC Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
2023	Ambee Pharmaceuticals PLC Reports Earnings Results for the First Quarter Ended September 30, 2023	CI

Ambee Pharmaceuticals plc Recommends Cash Dividend for the Year Ended June 30, 2023

November 05, 2023 at 10:07 am EST

Ambee Pharmaceuticals PLC announced that Board of Directors has recommended 15% Cash Dividend for the year ended June 30, 2023. Date of AGM: 14.12.2023. Record date: 23.11.2023.

Latest news about Ambee Pharmaceuticals Plc

Ambee Pharmaceuticals PLC Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 05	CI
Ambee Pharmaceuticals PLC Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
Ambee Pharmaceuticals plc Recommends Cash Dividend for the Year Ended June 30, 2023	Nov. 05	CI
Ambee Pharmaceuticals Ltd. will Change its Name to Ambee Pharmaceuticals PLC	23-08-09	CI
Ambee Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-07-10	CI
Ambee Pharmaceuticals Limited Appoints Mohammad Amir Hossain as Company Secretary	23-04-03	CI
Ambee Pharmaceuticals Limited Appoints Khairul Aziz as Chief Financial Officer	23-03-27	CI
Ambee Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-13	CI
Ambee Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-12-10	CI
Ambee Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-26	CI
Ambee Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022	22-11-22	CI
Ambee Pharmaceuticals Limited Appoints Ms. Kazi Tanzzina Ferdous as Managing Director	22-07-12	CI
Ambee Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2021	21-12-13	CI
Ambee Pharmaceuticals Limited Reports Earnings Results for the Year Ended on June 30, 2020	21-06-08	CI
Ambee Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended on June 30, 2020	21-06-08	CI
Ambee Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2019	19-11-27	CI
Ambee Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2018	18-11-13	CI
Ambee Pharmaceuticals Ltd. Reports Earnings Results for the Year Ended June 30, 2018	18-11-13	CI
Ambee Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 2018	18-04-24	CI
Ambee Pharmaceuticals Ltd. Announces Unaudited Financial Results for the Quarter and Six Months Ended December 31, 2017	18-01-29	CI
Ambee Pharmaceuticals Ltd. Announces Unaudited Earnings Results for the First Quarter Ended September 30, 2017	17-11-12	CI
Ambee Pharmaceuticals Ltd Recommends 30% Cash Dividend for the Year Ended on June 30, 2017	17-11-05	CI
Ambee Pharmaceuticals Ltd. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended March 31, 2017	17-04-25	CI
Ambee Pharmaceuticals Ltd. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended December 31, 2016	17-01-30	CI
Ambee Pharmaceuticals Ltd. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2012	12-05-15	CI

Chart Ambee Pharmaceuticals Plc

Duration

Period

More charts

Ambee Pharmaceuticals Limited is a Bangladesh-based company, which is engaged in pharmaceutical operations. The principal activities of the Company are to manufacture, buy, sell, export, or otherwise deal in all kinds of drugs, medicines, pharmaceuticals, chemicals, medical or any other preparations and to refine, manipulate, or treat all such substances used in pharmaceutical industry and to do all such acts necessary in connection with any business or chemist druggist, chemical and medicine manufactures, pharmacists, and others. Its products include ANTAC, AMBEECLOX, STOMACID, FLUXIN, MYCEF, A-ROX, MYZID, HIFLOX, HIFLOX-XR, LEXLO, TETRAM, DOXILLIN, TACTIN, NALIDEX, AFLUZOLE, KLION, AFUVIN, TRIBEN-DS, AMETROL-VT, MESPA, SURAL, TRIBEN, AMINOPHYLLINE, CODEX, NILKOF, DEXTROMETHORPHAN, AMBEECAL, ACES PLUS, CALCITATE, C-BON, AMBEECAL D, CALCIUM AMBEE, VITEX, FOLAC, VITEX GOLD, AROLAK, HITFLAM, NAPROXIN, FUNGAKIL, FUNGAKIL, CINON, NOSTIS, AMASON, NOCTIN, DIPHEDAN, DOPEGYT and others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
AMBEE PHARMACEUTICALS PLC	-11.73%	15.74M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B